Vibalogics increases capacity with a new 200-L line for virus manufacturing
Company has also invested in an Äkta-ready chromatography system for downstream processing and liquid handling equipment to deal with increased volumes.
GERMANY-based CDMO Vibalogics has increased its single-use bioreactor and purification capacity with a new manufacturing line to meet increasing demand for its specialist oncolytic virus and viral vector manufacturing services.
The new manufacturing line features 50-L and 200-L single use bioreactors and a Siemens process control system, further enhancing the company’s state-of-the-art offering within the field of GMP-compliant manufacturing of complex live biologicals.
To complement the new bioreactor, the company has also invested in an Äkta-ready chromatography system for downstream processing and liquid handling equipment to deal with the increased volumes involved in this scale of operation.
Operating from a multi-product BSL-2 facility in northern Germany, Vibalogics specialises in aseptic drug substance and drug product manufacturing of viruses.
Dr Stefan Beyer, managing director at Vibalogics said: “As a leading specialist in the aseptic processing of live biological products, we continue to increase our capacity and scale of operations in line with the growing global demand for these services and already have orders in place for the 200-L system up to the second half of 2020.
“This additional processing capability ensures that we have the necessary infrastructure in place to handle larger batch volumes for our customers.
“We are growing quickly and are now in a position to service a broader customer base for later stage clinical trials and will continue to invest in the technology and equipment needed to meet our customers’ requirements.”
This latest expansion follows the company’s previous addition of an automatic filling line to extend its aseptic fill and finish capability and reinforce its ability to support early-phase biologic supply needs for Phase I and II clinical trials.
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance